Your session is about to expire
← Back to Search
Bimatoprost for Graves' Eye Disease
Study Summary
This trial is testing whether a drug used for glaucoma can also be used to reduce the fat around the eyes in patients with Graves' disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have active Graves' disease.I have bulging eyes due to thyroid eye disease.I am currently taking steroids.
- Group 1: Bimatoprost in more proptotic eye
- Group 2: Control
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial pioneering a new course of treatment?
"Bimatoprost Ophthalmic has been under scientific scrutiny since 2015, when AbbVie sponsored the first clinical trial involving 215 patients. After achieving an approval in Phase 3 drug trials, 5 more studies have launched spanning numerous cities and countries globally."
How many individuals have enrolled in this trial thus far?
"Affirmative. Clinicaltrials.gov's records indicate that this research is in active recruitment mode, having been posted on November 1st 2017 and revised May 11th 2022. This study demands the enrollment of 3 individuals from a single medical facility."
What indications does Bimatoprost Ophthalmic typically address?
"Bimatoprost Ophthalmic can be utilized to manage open angle glaucoma (OAG), eyelash enhancement, and raised intra ocular pressure (IOP)."
Is it still possible to partake in this experiment?
"This trial, as confirmed on clinicaltrials.gov, is actively searching for participants - it was first listed in November of 2017 and updated most recently in May 2022."
Are there any prior investigations concerning Bimatoprost Ophthalmic?
"At this juncture, 5 clinical studies are currently researching the effects of Bimatoprost Ophthalmic with 4 trials in their final stages. Although most of the research sites for Bimatoprost Ophthalmic are located near Wellington, Texas, there is a scattering of other locations hosting these experiments across America totalling to 472 total centres."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger